221 related articles for article (PubMed ID: 21209626)
1. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
Barber A; Meehan KR; Sentman CL
Gene Ther; 2011 May; 18(5):509-16. PubMed ID: 21209626
[TBL] [Abstract][Full Text] [Related]
2. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.
Barber A; Zhang T; Megli CJ; Wu J; Meehan KR; Sentman CL
Exp Hematol; 2008 Oct; 36(10):1318-28. PubMed ID: 18599182
[TBL] [Abstract][Full Text] [Related]
3. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
Zhang T; Barber A; Sentman CL
Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
[TBL] [Abstract][Full Text] [Related]
4. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
Barber A; Rynda A; Sentman CL
J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
[TBL] [Abstract][Full Text] [Related]
5. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
Zhang T; Sentman CL
J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
[TBL] [Abstract][Full Text] [Related]
6. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
Barber A; Sentman CL
J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
[TBL] [Abstract][Full Text] [Related]
7. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
8. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
Barber A; Zhang T; Sentman CL
J Immunol; 2008 Jan; 180(1):72-8. PubMed ID: 18097006
[TBL] [Abstract][Full Text] [Related]
10. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Spear P; Barber A; Rynda-Apple A; Sentman CL
Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
[TBL] [Abstract][Full Text] [Related]
11. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
12. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
[TBL] [Abstract][Full Text] [Related]
13. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
14. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.
Meehan KR; Talebian L; Tosteson TD; Hill JM; Szczepiorkowski Z; Sentman CL; Ernstoff MS
Biol Blood Marrow Transplant; 2013 Jan; 19(1):129-37. PubMed ID: 22975165
[TBL] [Abstract][Full Text] [Related]
17. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
18. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Garg TK; Szmania SM; Khan JA; Hoering A; Malbrough PA; Moreno-Bost A; Greenway AD; Lingo JD; Li X; Yaccoby S; Suva LJ; Storrie B; Tricot G; Campana D; Shaughnessy JD; Nair BP; Bellamy WT; Epstein J; Barlogie B; van Rhee F
Haematologica; 2012 Sep; 97(9):1348-56. PubMed ID: 22419581
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
[TBL] [Abstract][Full Text] [Related]
20. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.
Lehner M; Götz G; Proff J; Schaft N; Dörrie J; Full F; Ensser A; Muller YA; Cerwenka A; Abken H; Parolini O; Ambros PF; Kovar H; Holter W
PLoS One; 2012; 7(2):e31210. PubMed ID: 22355347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
